Work

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor

Year: 2008

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v112.11.4939.4939

Authors: Paul A. Hamlin, Carol Aghajanian, David Hong, Anas Younes, Michael A. Palladino, Angie M. Longenecker, Gillian Cropp, G. Kenneth Lloyd, Alison L. Hannah, Matthew A. Spear, Razelle Kurzrock

Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Ubiquitin and proteasome pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2553026575

FWCI: 0.373

Cites:

Cited by: 6

Related to: 10